Multi-kinase targets (MKI targets)

Multi-kinase targets represent a broad collective of enzymes, primarily protein kinases, that are simultaneously inhibited by a single pharmacological agent to achieve a synergistic therapeutic effect. This group typically includes receptor tyrosine kinases (RTKs) such as Vascular Endothelial Growth Factor Receptors (VEGFR-1, -2, -3), Platelet-Derived Growth Factor Receptors (PDGFR-alpha, -beta), and Fibroblast Growth Factor Receptors (FGFR), as well as intracellular kinases like RAF, KIT, and FLT3 (National Cancer Institute, 2024). These targets play pivotal roles in regulating cellular processes including proliferation, survival, and the formation of new blood vessels (angiogenesis), which are frequently dysregulated in malignant tumors (StatPearls, 2023). In the context of oncology, targeting multiple kinases allows for the simultaneous disruption of both the tumor cells themselves and the supporting tumor microenvironment, such as the vascular supply. For example, drugs like Sorafenib and Sunitinib target both the RAF/MEK/ERK pathway in tumor cells and the VEGFR/PDGFR pathways in endothelial cells to inhibit tumor growth and blood supply (Motzer et al., 2006, NEJM). While this multi-targeted approach is highly effective in treating complex, heterogeneous diseases like renal cell carcinoma and hepatocellular carcinoma, it often results in a wider range of off-target toxicities compared to highly selective inhibitors. Common adverse effects associated with affecting these targets include hypertension, dermatological reactions, and gastrointestinal distress, necessitating careful patient monitoring (PubChem, 2024).

Other names

Multiple protein kinasesPan-kinase targetsMulti-targeted tyrosine kinase targetsReceptor tyrosine kinase (RTK) clusters

Multi-kinase inhibitors (MKIs) typically act through competitive inhibition of the adenosine triphosphate (ATP) binding site on the catalytic domain of multiple kinases (Gotink & Verheul, 2010, Angiogenesis). By blocking the phosphorylation of tyrosine, serine, or threonine residues, these drugs simultaneously disrupt multiple downstream signaling cascades, such as the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways, which are critical for tumor growth and survival (Wilhelm et al., 2006, Nature Reviews Drug Discovery).